Company News_CGeneTech_small molecular innovative drugs

News Center

Home page

Dr. Yu Qiang: Facing Industry Changes, Embracing the AI Future

Recently, the 9th EBC BIOCHINA (EBC) Yimao Bio-Industry Conference was held at the Suzhou International Expo Center. Dr. Yu Qiang, Founder and CEO of Shengshi Taike Innovation and Secretary-General of the Xinyao Club, attended the event and organized the "Small-Molecule Innovative Drug Development Forum." The forum特邀 over ten distinguished industry leaders to jointly discuss cutting-edge technologies and emerging targets in small-molecule drug development, exploring together with attendees how these molecules can continue to play a vital role in advancing future pharmaceutical research—and ultimately better address clinical needs.

Time：2024-03-22 17:04

Jiangsu Province Laboratory Animal License Annual Inspection Report

Time：2024-02-05 23:23

World Diabetes Day | Empowering Diabetes Patients Through Innovation at the Source

Time：2023-11-16 14:40

Shengshi Taikang Information Disclosure on Prevention and Control of Environmental Pollution Caused by Hazardous Waste

Time：2023-08-19 11:47

Shengshi Taikang Honored as a "Pioneer Enterprise for Independent Innovation in China's Pharmaceutical Industry"

Shengshi Taikang has been honored as a "Pioneer Enterprise for Independent Innovation in China's Pharmaceutical Industry."

Time：2023-08-16 17:42

Innovation Receives Further Recognition: Sitagliptin Selected for Special Support under Jiangsu Province's Science and Technology Program

Time：2023-08-16 17:37

Complementary advantages: World's first SGLT-2/DPP-4 dual-target inhibitor approved for clinical trials

Recently, CGT-2201, a Class 1 innovative drug developed by Shengshi Taikang and targeting both SGLT-2 and DPP-4, has received implicit approval from the National Medical Products Administration for clinical trials. As a dual-target inhibitor, CGT-2201 addresses two key metabolic pathways closely linked to diabetes, making it particularly effective in treating diabetes and its related complications, such as diabetic nephropathy and non-alcoholic fatty liver disease. China currently boasts the largest diabetic population globally, with 141 million people diagnosed as of 2021. Among these patients, an estimated 20–40% may develop diabetic kidney disease—a serious complication that significantly impacts quality of life and increases healthcare costs. While sodium-glucose co-transporter 2 (SGLT-2) inhibitors have demonstrated robust renal protective effects in clinical settings, their use is often limited by inherent risks of reproductive and urinary system infections. To address this gap, Shengshi Taikang has leveraged its proprietary small-molecule chimera drug technology platform to design and develop CGT-2201, a novel compound that combines the benefits of SGLT-2 inhibition with the favorable properties of DPP-4 inhibition. By simultaneously reducing glucose reabsorption in the kidneys via SGLT-2 blockade and preserving GLP-1 levels through DPP-4 inhibition, CGT-2201 achieves a synergistic dual-action mechanism, enhancing blood sugar control while minimizing urinary and genital tract infection risks—key side effects associated with existing SGLT-2 inhibitors. Importantly, because CGT-2201 does not rely on renal excretion, it imposes no restrictions on patients with impaired kidney function, offering a safer treatment option for those who might otherwise be excluded from current therapies. Building on this strong market demand and the unique characteristics of its target pathways, Shengshi Taikang has positioned CGT-2201 as a flagship product within its pipeline. The company’s cutting-edge chimera drug technology enables the creation of multi-functional, multi-targeted compounds with complementary mechanisms of action. CGT-2201 exemplifies this approach: it integrates the distinct advantages of both SGLT-2 and DPP-4 inhibition, effectively lowering glucose reabsorption in the kidneys while preserving GLP-1 activity to support insulin secretion. Clinical trial data indicate that even low doses of CGT-2201 achieve significant glycemic control, while higher doses further enhance safety profiles. Notably, the drug’s impressive efficacy-to-dose ratio suggests it could become a leading choice among SGLT-2 inhibitors, potentially setting a new standard in diabetes management. Founded in 2010 in Suzhou Industrial Park, Shengshi Taikang has assembled a seasoned leadership team with decades of global expertise spanning the entire pharmaceutical lifecycle. The company is dedicated to advancing high-quality, differentiated small-molecule drug innovation and commercialization. Leveraging an integrated drug R&D platform and a forward-thinking business strategy, Shengshi Taikang has cultivated a diverse pipeline covering multiple therapeutic areas, including diabetes, cancer, and autoimmune diseases. In the diabetes space, the company’s lead candidate, shenglitinib, has already been submitted to the NMPA for New Drug Application (NDA) and is currently under review. Phase 3 clinical trials have shown that even low doses can meet primary efficacy endpoints, while higher doses consistently demonstrate excellent safety profiles. This remarkable "dose-sparing" effect positions shenglitinib as a potential best-in-class treatment for diabetes, offering both superior blood sugar control and enhanced renal protection—a critical advantage for patients managing both diabetes and kidney-related complications. With CGT-2201 now poised to enter clinical trials, Shengshi Taikang continues to expand its portfolio of innovative solutions aimed at addressing unmet medical needs across the diabetes landscape.

Time：2023-04-20 11:50

Dr. Yu Qiang: Industries Join Hands, Awaiting Flowers Along the Path

2023 was a pivotal year for Shengshi Taikang, marking a significant step forward. The company’s first domestically produced teriflunomide, already available on the market, will soon be integrated into national health insurance programs across China, bringing much-needed relief to rare disease patients suffering from multiple sclerosis.

Time：2023-03-09 12:50

< 1...3 4 5...8 >

Contact Information

Address: Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Email: hr@cgenetech.com.cn

Tel： +86-512-62956960（Recruitment）

+86-512-62956961（marketing）

SEO tags

中企跨境-全域组件制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地